Nunno, Vincenzo Di; Franceschi, Enrico; Gatto, Lidia; Brandes, Alba Ariela published the artcile< BET inhibitors: the promise of a new generation of immunotherapy in glioblastoma>, Recommanded Product: (9Z,12Z)-Methyl octadeca-9,12-dienoate, the main research area is glioblastoma BET inhibitor immunotherapy; BET; BET inhibitors; BRD; glioblastoma; immunotherapy.
The clin. evaluation of immune checkpoint inhibitors in patients with glioblastoma (GBM) has resulted in another failed attempt to change the clin. course of one of the most fatal diseases known. Unfortunately, no drugs have shown clin. efficacy in advanced/relapsed disease. As a consequence, no therapeutic approaches have modified the standard of care represented by surgery followed by radiation therapy with concurrent and adjuvant temozolomide. The inhibition of BET proteins can lead to reduced activity of H3K27Ac, resulting in restored activity of different immune cells. Although Phase I studies showed a safety profile of these agents, their clin. effect on GBM is unknown. The interaction between microenvironment and tumor cells offers novel possible targets for GBM treatment. Nonetheless, BET inhibitors are currently under investigation as single agents, and there are no studies reporting the toxicity profile and efficacy of combinations of BET inhibitors and immune checkpoint inhibitors or other systemic agents.
Immunotherapy published new progress about Bromodomain and extra-terminal domain-containing protein inhibitors. 112-63-0 belongs to class esters-buliding-blocks, and the molecular formula is C19H34O2, Recommanded Product: (9Z,12Z)-Methyl octadeca-9,12-dienoate.
Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics